desde Redalyc
{{t.titulosHerramientas.nube}}
{{t.titulosHerramientas.numeros}}
X
{{t.formats.viewer}}
PDF
HTML
{{t.formats.mobile}}
ePUB
XML JATS
{{t.titulosSecciones.citas}}
{{t.titulosSecciones.autorias}}
{{t.titulosSecciones.descargas}}
{{t.titulosSecciones.revision}}
Abstract: Objective: To determine the impact of the implementation of an influen za vaccination campaign in a hospital pharmacy service on patients who are starting or receiving treatment with biological therapies.Method: A 15-month quasi-experimental study of patien
en es
Abstract: Objective: Patients Included In MAINRITSAN2 trial received either an Individually tailored or a fixed-schedule therapy with rituximab as mainte nance treatment of antineutrophil cytoplasm antibody associated vasculi tides. The aim of this study was to compar
en es
Abstract: Objective: To identify the hazards and define the theoretical occupa tional risks arising from the process of handling hazard drugs in hospital pharmacy services on the basis of expert consensus.Method: An expert consensus was conducted (nominal group and d
en es
Abstract: Objective: Inflammatory bowel disease comprises a group of chronic relapsing inflammatory disorders affecting the bowel. In the last decade, the advent of biological drugs brought about a drastic change in the treatment of the disease. Adalimumab, golimumab
en es
Abstract: Objective: To identify and describe cost-effectiveness studies that eva luate disease modifying therapies in the context of relapsing-remitting mul tiple sclerosis.Method: A systematic review of the literature was carried out by searching MEDLINE, Embase, t
en es
|
|
||
|---|---|---|
|
|
||
| {{criterio.prioridadCriterio}}. {{criterio.observaciones}} |  |
|
| {{criterio.prioridadCriterio}}. {{criterio.observaciones}} | |
|
| {{criterio.prioridadCriterio}}. {{criterio.observaciones}} | |
|
| {{criterio.prioridadCriterio}}. {{criterio.observaciones}} | |
|
| {{criterio.prioridadCriterio}}. {{criterio.observaciones}} | |
|